Sugi Predict

Sugi Predict / Compounds / SCHEMBL632629

SCHEMBL632629

SCHEMBL632629

CC(C)(C)OC(=O)Nc1ccccc1Br

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDK1 Q15118 1/20 0.54
▸ PDK2 Q15119 1/20 0.54
▸ PDK3 Q15120 1/20 0.54
▸ PDK4 Q16654 1/20 0.54
▸ HTT P42858 5/20 0.52
▸ KMT2A Q03164 4/20 0.52
▸ RAB9A P51151 3/20 0.52
▸ MEN1 O00255 3/20 0.52
▸ NPC1 O15118 2/20 0.52
▸ LMNA P02545 2/20 0.49
▸ POLB P06746 1/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.47
▸ BRD9 Q9H8M2 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ METAP1 P53582 1/20 0.44
▸ EGFR P00533 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ CASP3 P42574 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30976363 1.00 PDK1 (0.54) PDK1PDK2PDK3PDK4HTT
SCHEMBL2880191 0.87 LMNA (0.54) HTTKMT2ARAB9AMEN1NPC1
SCHEMBL14243354 0.85 NPC1 (0.46) PDK1PDK2PDK3PDK4HTT
SCHEMBL30341113 0.85 MEN1 (0.46) PDK1PDK2PDK3PDK4HTT
SCHEMBL23624071 0.84 MEN1 (0.45) PDK1PDK2PDK3PDK4HTT
SCHEMBL5367134 0.84 RXFP1 (0.50) PDK1PDK2PDK3PDK4HTT
SCHEMBL31605689 0.84 MEN1 (0.45) PDK1PDK2PDK3PDK4HTT
SCHEMBL575004 0.84 RXFP1 (0.46) PDK1PDK2PDK3PDK4HTT
SCHEMBL29909461 0.84 RXFP1 (0.46) PDK1PDK2PDK3PDK4HTT
SCHEMBL15145823 0.84 L3MBTL1 (0.51) PDK1PDK2PDK3PDK4HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114651898-B Triazole feed additive for improving immunity as well as preparation method and application thereof 天津溢佳同惠科技集团有限公司 2024-04-05 — — CN claimed
CN-114651898-A Triazole feed additive for improving immunity and preparation method and application thereof 河南湾流生物科技有限公司 2022-06-24 — — CN claimed
EP-4747260-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 — — EP disclosed
EP-4618977-A1 LRRK2 INHIBITORS AND USES THEREOF Neuron23, Inc. (US) 2025-09-24 — — EP disclosed
WO-2025125302-A1 NOVEL COMPOUNDS GENOME THERAPEUTICS LTD (GB) 2025-06-19 — — WO disclosed
WO-2025021666-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2025-01-30 — — WO disclosed
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 — — US disclosed
US-20240228493-A1 LRRK2 INHIBITORS AND USES THEREOF NEURON23, INC. 2024-07-11 — — US disclosed
US-20240228493-A1 LRRK2 INHIBITORS AND USES THEREOF NEURON23, INC. 2024-07-11 — — US disclosed
US-20240228493-A1 LRRK2 INHIBITORS AND USES THEREOF NEURON23, INC. 2024-07-11 — — US disclosed
US-20240208972-A1 LRRK2 INHIBITORS AND USES THEREOF NEURON23, INC. 2024-06-27 — — US disclosed
EP-0968198-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING $g(b)-AMYLOID PEPTIDE Elan Pharmaceuticals, Inc. (US) 2000-01-05 — — EP disclosed
WO-1999067221-A1 COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS ELAN PHARMACEUTICALS, INC. (US) 1999-12-29 — — WO disclosed
WO-1999066934-A1 CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS ELAN PHARMACEUTICALS, INC. (US) 1999-12-29 — — WO disclosed
WO-1999067219-A1 COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS ELAN PHARMACEUTICALS, INC. (US) 1999-12-29 — — WO disclosed
WO-1999067220-A1 COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS ELAN PHARMACEUTICALS, INC. (US) 1999-12-29 — — WO disclosed
EP-0951466-A2 CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS Elan Pharmaceuticals, Inc. (US) 1999-10-27 — — EP disclosed
WO-1999032453-A1 POLYCYCLIC α-AMINO-⊂-CAPROLACTAMS AND RELATED COMPOUNDS ELAN PHARMACEUTICALS, INC. (US) 1999-07-01 — — WO disclosed
WO-1998038177-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING β-AMYLOID PEPTIDE ELAN PHARMACEUTICALS, INC. (US) 1998-09-03 — — WO disclosed
WO-1998028268-A2 CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 1998-07-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208972-A1 LRRK2 INHIBITORS AND USES THEREOF LRRK2, PINK1, PARK7 PDK1 491/4885PDK2 469/4885PDK3 435/4885
US-20240228493-A1 LRRK2 INHIBITORS AND USES THEREOF LRRK2, PINK1, PARK7 PDK1 491/4885PDK2 469/4885PDK3 435/4885
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES BCAT1, BCAT2, PELP1 PDK1 2114/4885PDK2 2062/4885PDK3 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.